Paul F Pinsky1, Kelly Yu2, Barnett S Kramer3, Amanda Black2, Saundra S Buys4, Edward Partridge5, John Gohagan6, Christine D Berg2, Philip C Prorok3. 1. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, United States. Electronic address: pp4f@nih.gov. 2. Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, United States. 3. Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, United States. 4. University of Utah School of Medicine, United States. 5. University of Alabama at Birmingham School of Medicine, United States. 6. Office of Disease Prevention, National Institutes of Health, United States.
Abstract
BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial originally reported no mortality benefit of ovarian cancer screening after a median of 12.4years of follow-up. The UKCTOCS screening trial failed to show a statistically significant mortality reduction in the primary analysis but reported an apparent increased mortality benefit in trial years 7-14 compared to 0-7. Here we report an updated analysis of PLCO with extended mortality follow-up. METHODS:Participants were randomized from 1993 to 2001 at ten U.S. centers to an intervention or usual care arm. Intervention arm women were screened for ovarian cancer with annual trans-vaginal ultrasound (TVU) (4years) and CA-125 (6years), with a fixed cutoff at 35U/mL for CA-125. The original follow-up period was for up to 13years (median follow-up 12.4years); in this analysis follow-up for mortality was extended by up to 6years. RESULTS: 39,105 (intervention) and 39,111 (usual care) women were randomized, of which 34,253 and 34,304, respectively, had at least one ovary at baseline. Median follow-up was 14.7years in each arm and maximum follow-up 19.2years in each arm. A total of 187 (intervention) and 176 (usual care) deaths from ovarian cancer were observed, for a risk-ratio of 1.06 (95% CI: 0.87-1.30). Risk-ratios were similar for study years 0-7 (RR=1.04), 7-14 (RR=1.06) and 14+ (RR=1.09). The risk ratio for all-cause mortality was 1.01 (95% CI: 0.97-1.05). Ovarian cancer specific survival was not significantly different across trial arms (p=0.16). CONCLUSION: Extended follow-up of PLCO indicated no mortality benefit from screening for ovarian cancer with CA-125 and TVU. Published by Elsevier Inc.
RCT Entities:
BACKGROUND: The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial originally reported no mortality benefit of ovarian cancer screening after a median of 12.4years of follow-up. The UKCTOCS screening trial failed to show a statistically significant mortality reduction in the primary analysis but reported an apparent increased mortality benefit in trial years 7-14 compared to 0-7. Here we report an updated analysis of PLCO with extended mortality follow-up. METHODS:Participants were randomized from 1993 to 2001 at ten U.S. centers to an intervention or usual care arm. Intervention arm women were screened for ovarian cancer with annual trans-vaginal ultrasound (TVU) (4years) and CA-125 (6years), with a fixed cutoff at 35U/mL for CA-125. The original follow-up period was for up to 13years (median follow-up 12.4years); in this analysis follow-up for mortality was extended by up to 6years. RESULTS: 39,105 (intervention) and 39,111 (usual care) women were randomized, of which 34,253 and 34,304, respectively, had at least one ovary at baseline. Median follow-up was 14.7years in each arm and maximum follow-up 19.2years in each arm. A total of 187 (intervention) and 176 (usual care) deaths from ovarian cancer were observed, for a risk-ratio of 1.06 (95% CI: 0.87-1.30). Risk-ratios were similar for study years 0-7 (RR=1.04), 7-14 (RR=1.06) and 14+ (RR=1.09). The risk ratio for all-cause mortality was 1.01 (95% CI: 0.97-1.05). Ovarian cancer specific survival was not significantly different across trial arms (p=0.16). CONCLUSION: Extended follow-up of PLCO indicated no mortality benefit from screening for ovarian cancer with CA-125 and TVU. Published by Elsevier Inc.
Authors: Saundra S Buys; Edward Partridge; Mark H Greene; Philip C Prorok; Douglas Reding; Thomas L Riley; Patricia Hartge; Richard M Fagerstrom; Lawrence R Ragard; David Chia; Grant Izmirlian; Mona Fouad; Christine C Johnson; John K Gohagan Journal: Am J Obstet Gynecol Date: 2005-11 Impact factor: 8.661
Authors: Charles W Drescher; Chirag Shah; Jason Thorpe; Kathy O'Briant; Garnet L Anderson; Christine D Berg; Nicole Urban; Martin W McIntosh Journal: J Clin Oncol Date: 2012-12-17 Impact factor: 44.544
Authors: Paul F Pinsky; Claire Zhu; Steve J Skates; Amanda Black; Edward Partridge; Saundra S Buys; Christine D Berg Journal: Int J Cancer Date: 2012-11-05 Impact factor: 7.396
Authors: Anthony B Miller; Ronald Feld; Robert Fontana; John K Gohagan; Ismail Jatoi; Walter Lawrence; Amy Miller; Philip C ProroK; Ashwani Rajput; Morris Sherman; Gilbert Welch; Patrick Wright; Susan Yurgalevitch; Peter Albertsen Journal: Rev Recent Clin Trials Date: 2015
Authors: Malcolm C Pike; Paul D P Pharoah; Celeste Leigh Pearce; Daniel O Stram; Roberta B Ness; Douglas A Stram; Lynda D Roman; Claire Templeman; Alice W Lee; Usha Menon; Peter A Fasching; Jessica N McAlpine; Jennifer A Doherty; Francesmary Modugno; Joellen M Schildkraut; Mary Anne Rossing; David G Huntsman; Anna H Wu; Andrew Berchuck Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01-26 Impact factor: 4.254
Authors: Saundra S Buys; Edward Partridge; Amanda Black; Christine C Johnson; Lois Lamerato; Claudine Isaacs; Douglas J Reding; Robert T Greenlee; Lance A Yokochi; Bruce Kessel; E David Crawford; Timothy R Church; Gerald L Andriole; Joel L Weissfeld; Mona N Fouad; David Chia; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Patricia Hartge; Paul F Pinsky; Claire S Zhu; Grant Izmirlian; Barnett S Kramer; Anthony B Miller; Jian-Lun Xu; Philip C Prorok; John K Gohagan; Christine D Berg Journal: JAMA Date: 2011-06-08 Impact factor: 157.335
Authors: Ian J Jacobs; Usha Menon; Andy Ryan; Aleksandra Gentry-Maharaj; Matthew Burnell; Jatinderpal K Kalsi; Nazar N Amso; Sophia Apostolidou; Elizabeth Benjamin; Derek Cruickshank; Danielle N Crump; Susan K Davies; Anne Dawnay; Stephen Dobbs; Gwendolen Fletcher; Jeremy Ford; Keith Godfrey; Richard Gunu; Mariam Habib; Rachel Hallett; Jonathan Herod; Howard Jenkins; Chloe Karpinskyj; Simon Leeson; Sara J Lewis; William R Liston; Alberto Lopes; Tim Mould; John Murdoch; David Oram; Dustin J Rabideau; Karina Reynolds; Ian Scott; Mourad W Seif; Aarti Sharma; Naveena Singh; Julie Taylor; Fiona Warburton; Martin Widschwendter; Karin Williamson; Robert Woolas; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Mahesh Parmar; Steven J Skates Journal: Lancet Date: 2015-12-17 Impact factor: 79.321
Authors: Patricia G Moorman; Nadine J Barrett; Frances Wang; J Anthony Alberg; Elisa V Bandera; J B Barnholtz-Sloan; Melissa Bondy; Michele L Cote; Ellen Funkhouser; Linda E Kelemen; Lauren C Peres; Edwards S Peters; A G Schwartz; Paul D Terry; Sydnee Crankshaw; Sarah E Abbott; Joellen M Schildkraut Journal: J Womens Health (Larchmt) Date: 2018-11-27 Impact factor: 2.681
Authors: Talayeh S Ghezelayagh; Lauren E Stewart; Barbara M Norquist; Deborah J Bowen; Vivian Yu; Kathy J Agnew; Kathryn P Pennington; Elizabeth M Swisher Journal: Fam Cancer Date: 2020-02-24 Impact factor: 2.375
Authors: Yingwei Hu; Jianbo Pan; Punit Shah; Minghui Ao; Stefani N Thomas; Yang Liu; Lijun Chen; Michael Schnaubelt; David J Clark; Henry Rodriguez; Emily S Boja; Tara Hiltke; Christopher R Kinsinger; Karin D Rodland; Qing Kay Li; Jiang Qian; Zhen Zhang; Daniel W Chan; Hui Zhang Journal: Cell Rep Date: 2020-10-20 Impact factor: 9.423
Authors: Sigurgeir Olafsson; Kristjan F Alexandersson; Johann G K Gizurarson; Katrin Hauksdottir; Orvar Gunnarsson; Karl Olafsson; Julius Gudmundsson; Simon N Stacey; Gardar Sveinbjornsson; Jona Saemundsdottir; Einar S Bjornsson; Sigurdur Olafsson; Sigurdur Bjornsson; Kjartan B Orvar; Arnor Vikingsson; Arni J Geirsson; Sturla Arinbjarnarson; Gyda Bjornsdottir; Thorgeir E Thorgeirsson; Snaevar Sigurdsson; Gisli H Halldorsson; Olafur T Magnusson; Gisli Masson; Hilma Holm; Ingileif Jonsdottir; Olof Sigurdardottir; Gudmundur I Eyjolfsson; Isleifur Olafsson; Patrick Sulem; Unnur Thorsteinsdottir; Thorvaldur Jonsson; Thorunn Rafnar; Daniel F Gudbjartsson; Kari Stefansson Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-10-30 Impact factor: 4.254
Authors: Usha Menon; Aleksandra Gentry-Maharaj; Matthew Burnell; Naveena Singh; Andy Ryan; Chloe Karpinskyj; Giulia Carlino; Julie Taylor; Susan K Massingham; Maria Raikou; Jatinderpal K Kalsi; Robert Woolas; Ranjit Manchanda; Rupali Arora; Laura Casey; Anne Dawnay; Stephen Dobbs; Simon Leeson; Tim Mould; Mourad W Seif; Aarti Sharma; Karin Williamson; Yiling Liu; Lesley Fallowfield; Alistair J McGuire; Stuart Campbell; Steven J Skates; Ian J Jacobs; Mahesh Parmar Journal: Lancet Date: 2021-05-12 Impact factor: 79.321